期刊文献+

氧化铝复合陶瓷在全髋关节置换中的应用 被引量:2

Alumina matrix composite ceramic-on-ceramic bearings in total hip arthroplasty
下载PDF
导出
摘要 目的为了改善假体的生存率,减少陶瓷部件相关的并发症,新一代氧化铝复合陶瓷开始应用于临床,文中分析氧化铝复合陶瓷对陶瓷全髋关节置换的早期临床疗效。方法自2009年4月至2011年8月应用第4代氧化铝复合陶瓷对陶瓷对50例(59髋)髋关节疾病患者行全髋关节置换术,应用Harris评分及X线检查进行疗效评定。结果获得有效随访43例(52髋),平均随访21.4个月(12~40个月)。Harris评分由术前平均(43.0±16.3)分(11~64分)提高到末次随访时平均(92.6±5.3)分(80~100分)。未发生陶瓷组件的碎裂及假体脱位,1髋(1.9%)出现异响,1例发生症状性血栓。结论氧化铝复合陶瓷对陶瓷界面的短期临床效果满意,大头颈陶瓷假体的使用减少了术后脱位率,关节稳定性良好。 Objective A new alumina matrix composite material was developed to improve implant longevity and reduce the risk of component-related complications. The aim of this study was evaluate to retrospectively the short-term clinical results of alumina matrix composite ceramic-on-ceramic bearings in total hip arthroplasty. Methods From April 2009 to August 2011, we performed 59 total hip arthroplasties on 50 patients using alumina matrix composite eeramic-on-eeramic bearings at our institution. The clinical re- suits were evaluated by Harris hip score and X-rays. All patients were evaluated clinically and radiographieally at follow-up. Results At the time of the latest follow-up, forty-three (52 hips) patients were available for follow-up. Patients had a mean follow-up of 21.4 months ( range, 12 - 40 years). The mean preoperative Harris hip score improved from 43.0 ~ 16.3 ( range, 11 - 64 ) points to 92.6 + 5.3 ( range, 80 - 100) points at latest follow-up. There was no ceramic fractures and dislocations ; one patient ( 1.9% ) reported squea- king, 1 patient developed symptoms of deep veinthrombosis. Conclusion The early clinical results of alumina matrix composite ce ramie-on-ceramic total hip arthroplasty are favorable. Large-diameter femoral head in alumina matrix composite ceramic-on-ceramic to- tal hip arthroplasty had good stability and few dislocations. But further follow-up is required before a definite judgement can be made regarding the mid-term to long-term results.
出处 《医学研究生学报》 CAS 北大核心 2013年第4期373-376,共4页 Journal of Medical Postgraduates
基金 南京军区医学科技创新项目(11Z028) 南京市科技发展项目(2012sc311020)
关键词 氧化铝复合陶瓷 全髋关节置换 治疗结果 Mumina matrix composite ceramic Total hip arthroplasty Treatment outcome
  • 相关文献

参考文献15

  • 1闫韵飞,王瑞,赵建宁.人工关节无菌性松动动物模型的研究进展[J].医学研究生学报,2012,25(4):409-413. 被引量:6
  • 2朱亮亮,赵建宁.人工关节无菌性松动的分子机制及药物干预[J].医学研究生学报,2009,22(3):320-323. 被引量:14
  • 3孙国静,杨书丰,郭亭,赵建宁.不同浓度钛合金微粒对成骨细胞信号通路中转录表达因子RUNX2影响[J].医学研究生学报,2013,26(3):251-254. 被引量:10
  • 4Gallo J, Barry Goodman S, Lostak J, et al. Advantages and dis-advantages of ceramic on ceramic total hip arthroplasty : A review[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub,2012,156(3) : 204-212.
  • 5Tateiwa T,Clarke IC,Williams PA, et al. Ceramic total hip ar-throplasty in the United States : safety and risk issues revisited[J]. Am J Orthop (Belle Mead NJ),2008, 37(2) : E26-31.
  • 6Masson B. Emergence of the alumina matrix composite in totalhip arthroplasty[J]. Int Orthop, 2009, 33(2) : 359-363.
  • 7Hamilton WG, McAuley JP, Dennis DA, et al. THA with Deltaceramic on ceramic : results of a multicenter investigational deviceexemption trial[ J]. Clin Orthop Relat Res, 2010,468(2) :358-366.
  • 8Stewart T,Tipper J, Streicher R,et cd. Long-term wear of HIPedalumina on alumina bearings for THR under microseparation con-ditions[ J]. J Mater Sci Mater Med, 2001, 12(10-12) : 1053-1056.
  • 9Colwell CW, Hozack WJ, Mesko JW, et al. Ceramic-on-ceramictotal hip arthroplasty early dislocation rate[ J] . Clin Orthop RelatRes, 2007 , 465: 155-158.
  • 10Garino J, Kahaman MN, Bal BS. The Reliability of Modem Alu-mina Bearings in Total Hip Arthroplasty[ J]. Seminars in Arthro-plasty, 2006, 17(34): 113-119.

二级参考文献77

  • 1王扬天,王坚,马驰原.核因子-κB与糖尿病的关系[J].医学研究生学报,2007,20(3):310-314. 被引量:15
  • 2Greenfield M, Bechtold J. What other biologic and mechanical factors might contribute to osteolysis? [ J] Am Acad Ortho Surg, 2007,16( 1 ) :56-62.
  • 3Avbersek-Luznik I, Rus I, Marc J, et al. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? [ J] Nephrol Dial Transplant ,2005,20(3) :566-570.
  • 4Vitovski S, Jennifer SP, Sayers J, et al. Investigating the interaction between osteoprotegerin and receptor activator of NF-κB or tumor necrosis factor-related apoptosis-inducing ligand[ J]. Biol Chem,2007,282 ( 43 ) : 31601-31609.
  • 5Yamashita T, Yao ZQ, Li F, et al. NF-κB p50 and p52 regulate receptor activator of NF-κB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1 [J]. Biol Chem,2007,282 (25) : 18245- 18253.
  • 6Clohisy JC, Hirayama T, Frazier E, et al. NF-κB signaling blockade abolishes implant particle-induced osteoclastogenesis [J]. Orthop Res, 2004,22( 1 ) :13-20.
  • 7Clohisy JC, Frazier E, Hirayama T, et al. RANKL is an essential cytokine mediator of polymethylmethacrylate particleinducedoste oclastogenesis[ J]. Orthop Res,2003,21 (2) :202-212.
  • 8Yang SY, Chen W, Stashenko P. Specificity of RGS10A as a key component in the RANKL signaling mechanism for osteoclast differentiation[ J]. J Cell Science ,2007,120( 1 ) :3362-3371.
  • 9Sobacchi C, Frattini A, Guerrini MM, et al. Osteoclast-poor osteopetrosis due to mutations in the gene encoding RANKL [ J ]. Nat Geuet ,2007,39 ( 3 ) :960-962.
  • 10Mandelin J, Liljestrom M, Kroon M, et al. Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement [ J ]. Bone Joint Surg Br, 2003,85 (B) : 1196-1201.

共引文献25

同被引文献54

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部